Related references
Note: Only part of the references are listed.Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto et al.
LANCET (2020)
Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM) A Randomized, Placebo-Controlled, Double-Blind Pilot Study
Ali J. Marian et al.
CIRCULATION RESEARCH (2018)
Hypertrophic Cardiomyopathy Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Ali J. Marian et al.
CIRCULATION RESEARCH (2017)
Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats
Lin Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimer's Disease
Garth J. S. Cooper
DRUGS (2011)
Research Priorities in Hypertrophic Cardiomyopathy Report of a Working Group of the National Heart, Lung, and Blood Institute
Thomas Force et al.
CIRCULATION (2010)
Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy
Khalid Abozguia et al.
CIRCULATION (2010)
Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis Preliminary Validation in Humans
Andrew S. Flett et al.
CIRCULATION (2010)
31P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3T
Ganesh Nallur Shivu et al.
EUROPEAN JOURNAL OF RADIOLOGY (2010)
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β
Polakit Teekakirikul et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms
Raffaella Lombardi et al.
CIRCULATION (2009)
A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study
G. J. S. Cooper et al.
DIABETOLOGIA (2009)
Enhanced oxidative stress in hypertrophic cardiomyopathy
Pawel R. Dimitrow et al.
PHARMACOLOGICAL REPORTS (2009)
A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-β activation in the kidneys of rats used as a model of diabetes
D. Gong et al.
DIABETOLOGIA (2008)
The genetics of hypertrophic cardiomyopathy: Teare redux
H. Watkins et al.
HEART (2008)
Oxidative remodeling in pressure overload induced chronic heart failure
Brooke C. Henderson et al.
EUROPEAN JOURNAL OF HEART FAILURE (2007)
Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator
Mia Jullig et al.
PROTEOMICS CLINICAL APPLICATIONS (2007)
Aortic-banding induces myocardial oxidative stress and changes in concentration and activity of antioxidants in male Wistar rats
Maria H. V. M. Jacob et al.
LIFE SCIENCES (2006)
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy
V Senthil et al.
CIRCULATION RESEARCH (2005)
Regeneration of the heart in diabetes by selective copper chelation
GJS Cooper et al.
DIABETES (2004)
Concentations of copper, zinc, and magnesium in sera from patients with idiopathic dilated cardiomyopathy
G Topuzoglu et al.
BIOLOGICAL TRACE ELEMENT RESEARCH (2003)
Cardiac involvement in Wilson disease
Z Hlubocká et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2002)
Role of oxidative stress in myocardial hypertrophy and failure
DB Sawyer et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2002)
Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes
DR Pimentel et al.
CIRCULATION RESEARCH (2001)
Share Paper
